Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight
June 10, 2021 21:00 ET
|
DelveInsight Business Research LLP
Los Angeles, June 10, 2021 (GLOBE NEWSWIRE) -- Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight The majority...
Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma Companies | DelveInsight
May 26, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, May 26, 2021 (GLOBE NEWSWIRE) -- Cushing's Syndrome Pipeline Advances with a Heightened R&D, Expected Entry of Several Novel Therapies, and Inclined Interest of Pharma...
Orphan Drugs Market Global Sales Are Expected To Reach US$ 413.36 Billion by 2030, as stated by insightSLICE
March 02, 2021 09:54 ET
|
insightSLICE
PUNE, India, March 02, 2021 (GLOBE NEWSWIRE) -- The Global Orphan Drugs Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, business strategies, research...
Orphan Drugs Market to Reach USD 340.84 Billion by 2027; Increasing Number of Regulatory Approvals will Contribute to Market Growth, says Fortune Business Insights™
January 21, 2021 06:58 ET
|
Fortune Business Insights
Pune, Jan. 21, 2021 (GLOBE NEWSWIRE) -- The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a...
Orphan Drugs Market to Reach USD 340.84 Billion with 10.5% CAGR by 2027; Increasing Number of Regulatory Approvals will Contribute to Market Growth, says Fortune Business Insights™
October 26, 2020 07:50 ET
|
Fortune Business Insights
Pune, Oct. 26, 2020 (GLOBE NEWSWIRE) -- The global orphan drugs market size is projected to reach USD 340.84 billion by the end of 2027. Increasing number of regulatory approvals will have a...
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
December 11, 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
November 21, 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
November 06, 2019 07:00 ET
|
ProQR Therapeutics N.V.
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020QR-1123...
ProQR to Present at Two Investor Conferences in October
September 30, 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
September 09, 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...